Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Windtree Therapeutics Q4 2023 GAAP EPS $(0.95) Misses $(0.94) Estimate

Author: Benzinga Newsdesk | April 17, 2024 08:19am
Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.94) by 1.06 percent.

Posted In: WINT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist